Section Arrow
SNTI.NASDAQ
- Senti Biosciences Inc.
Quotes are at least 15-min delayed:2026/04/14 19:25 EDT
After Hours
Last
 0.9288
+0.0005 (+0.05%)
Bid
0.9226
Ask
0.94
High 0.94 
Low 0.9226 
Volume 1.39K 
Regular Hours (Closed)
Last
 0.9283
+0.0269 (+2.98%)
Day High 
0.94 
Prev. Close
0.9014 
1-M High
0.995 
Volume 
76.82K 
Bid
0.9226
Ask
0.94
Day Low
0.9151 
Open
0.93 
1-M Low
0.770167 
Market Cap 
28.07M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.85 
20-SMA 0.88 
50-SMA 0.91 
52-W High 5.1 
52-W Low 0.770167 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.73/-0.54
Enterprise Value
51.63M
Balance Sheet
Book Value Per Share
0.18
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
22.00K
Operating Revenue Per Share
0.10
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
HOTHHoth Therapeutics0.6459+0.134+26.18%-- 
After Hours 0.65 +0.0041 +0.63%
ALLOAllogene Therapeutics2.28-0.78-25.49%-- 
After Hours 2.19 -0.09 -3.95%
VRAXVirax Biolabs Group Limited0.148-0.0184-11.06%-- 
After Hours 0.1384 -0.0096 -6.49%
CMNDClearmind Medicine Inc.0.91-0.52-36.36%-- 
After Hours 0.8501 -0.0599 -6.58%
REPLReplimune Group1.95+0.25+14.71%-- 
After Hours 1.91 -0.04 -2.05%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow, and SENTI-301A for the treatment of hepatocellular carcinoma.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.